IP6K2

Summary

IP6K2 (inositol hexakisphosphate kinase 2, HGNC:17313) is a protein-coding gene on chromosome 3p21.31, encoding Inositol hexakisphosphate kinase 2 (Q9UHH9). Converts inositol hexakisphosphate (InsP6) to diphosphoinositol pentakisphosphate (InsP7/PP-InsP5).

This gene encodes a protein that belongs to the inositol phosphokinase (IPK) family. This protein is likely responsible for the conversion of inositol hexakisphosphate (InsP6) to diphosphoinositol pentakisphosphate (InsP7/PP-InsP5). It may also convert 1,3,4,5,6-pentakisphosphate (InsP5) to PP-InsP4 and affect the growth suppressive and apoptotic activities of interferon-beta in some ovarian cancers. Alternative splicing results in multiple transcript variants encoding different isoforms.

Source: NCBI Gene 51447 — RefSeq curated summary.

At a glance

• GWAS associations: 28
• Clinical variants (ClinVar): 55 total
• Druggable target: yes — 3 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_016291

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:17313
Approved symbol	IP6K2
Name	inositol hexakisphosphate kinase 2
Location	3p21.31
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000068745
Ensembl biotype	protein_coding
OMIM	606992
Entrez	51447

Gene structure

Transcript identifiers

Ensembl transcripts: 59 — 52 protein_coding, 3 nonsense_mediated_decay, 2 protein_coding_CDS_not_defined, 2 retained_intron

ENST00000328631, ENST00000340879, ENST00000412795, ENST00000412850, ENST00000413298, ENST00000413654, ENST00000416707, ENST00000417896, ENST00000424035, ENST00000431721, ENST00000432678, ENST00000433104, ENST00000434860, ENST00000436134, ENST00000437427, ENST00000440424, ENST00000443853, ENST00000443964, ENST00000446860, ENST00000449563, ENST00000449610, ENST00000450045, ENST00000453202, ENST00000454335, ENST00000455545, ENST00000476645, ENST00000479914, ENST00000491686, ENST00000904743, ENST00000904744, ENST00000904745, ENST00000904746, ENST00000904747, ENST00000904748, ENST00000904749, ENST00000904750, ENST00000904751, ENST00000921847, ENST00000921848, ENST00000921849, ENST00000921850, ENST00000921851, ENST00000921852, ENST00000921853, ENST00000921854, ENST00000921855, ENST00000921856, ENST00000921857, ENST00000946876, ENST00000946877, ENST00000946878, ENST00000946879, ENST00000946880, ENST00000946881, ENST00000946882, ENST00000946883, ENST00000946884, ENST00000946885, ENST00000946886

RefSeq mRNA: 8 — MANE Select: NM_016291 NM_001005909, NM_001005910, NM_001005911, NM_001146178, NM_001146179, NM_001190316, NM_001190317, NM_016291

CCDS: CCDS2777, CCDS33752, CCDS54579, CCDS54580, CCDS54581

Canonical transcript exons

ENST00000328631 — 6 exons

Exon	Start	End
ENSE00001819400	48688003	48688773
ENSE00001929186	48717157	48717221
ENSE00003486624	48689538	48689713
ENSE00003585030	48691307	48691482
ENSE00003589067	48695090	48695421
ENSE00003604107	48692954	48693179

Expression profiles

Bgee: expression breadth ubiquitous, 275 present calls, max score 98.71.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 40.0029 / max 380.6294, expressed in 1815 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
42172	39.7896	1815
42169	0.2133	95

Top tissues by expression

283 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right hemisphere of cerebellum	UBERON:0014890	98.71	gold quality
cerebellar hemisphere	UBERON:0002245	98.69	gold quality
cerebellar cortex	UBERON:0002129	98.64	gold quality
ganglionic eminence	UBERON:0004023	98.52	gold quality
tibial nerve	UBERON:0001323	98.44	gold quality
skin of abdomen	UBERON:0001416	98.29	gold quality
skin of leg	UBERON:0001511	98.28	gold quality
right uterine tube	UBERON:0001302	98.23	gold quality
mucosa of transverse colon	UBERON:0004991	98.20	gold quality
body of uterus	UBERON:0009853	98.10	gold quality
adenohypophysis	UBERON:0002196	97.94	gold quality
metanephros cortex	UBERON:0010533	97.94	gold quality
cortical plate	UBERON:0005343	97.92	gold quality
cerebellum	UBERON:0002037	97.89	gold quality
left ovary	UBERON:0002119	97.81	gold quality
right adrenal gland cortex	UBERON:0035827	97.81	gold quality
right lobe of thyroid gland	UBERON:0001119	97.78	gold quality
left lobe of thyroid gland	UBERON:0001120	97.76	gold quality
rectum	UBERON:0001052	97.75	gold quality
transverse colon	UBERON:0001157	97.70	gold quality
right adrenal gland	UBERON:0001233	97.67	gold quality
endocervix	UBERON:0000458	97.66	gold quality
right ovary	UBERON:0002118	97.55	gold quality
minor salivary gland	UBERON:0001830	97.49	gold quality
pituitary gland	UBERON:0000007	97.45	gold quality
lower esophagus mucosa	UBERON:0035834	97.45	gold quality
body of pancreas	UBERON:0001150	97.33	gold quality
ectocervix	UBERON:0012249	97.29	gold quality
small intestine Peyer’s patch	UBERON:0003454	97.20	gold quality
thyroid gland	UBERON:0002046	97.14	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): SP1

miRNA regulators (miRDB)

32 targeting IP6K2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4283	100.00	66.42	2097
HSA-MIR-3185	99.99	68.12	1959
HSA-MIR-1-3P	99.93	72.35	1914
HSA-MIR-206	99.93	72.50	1893
HSA-MIR-613	99.91	71.50	1710
HSA-MIR-95-5P	99.89	72.17	3973
HSA-MIR-202-3P	99.84	71.41	1290
HSA-MIR-24-3P	99.59	69.97	1934
HSA-MIR-105-5P	99.54	69.24	2060
HSA-MIR-7853-5P	99.54	69.30	2055
HSA-MIR-6833-5P	99.50	68.93	1161
HSA-MIR-409-3P	99.50	66.33	1192
HSA-MIR-4441	99.49	66.56	3216
HSA-MIR-653-5P	99.46	67.35	1300
HSA-MIR-10522-5P	99.26	68.50	2087
HSA-MIR-661	99.09	65.94	2062
HSA-MIR-4270	99.02	66.26	1987
HSA-MIR-4709-3P	98.88	68.04	1594
HSA-MIR-583	98.71	67.44	1791
HSA-MIR-9500	98.62	66.54	1845
HSA-MIR-6754-5P	98.60	65.54	1627
HSA-MIR-211-3P	98.14	66.77	1052
HSA-MIR-4518	98.12	66.82	1030
HSA-MIR-892B	98.00	67.11	821
HSA-MIR-1266-5P	97.71	66.92	1052
HSA-MIR-510-5P	97.66	65.82	916
HSA-MIR-3190-3P	97.61	66.95	1406
HSA-MIR-6736-3P	96.98	65.22	1342
HSA-MIR-12128	96.67	66.98	1471
HSA-MIR-4491	96.53	66.20	935

Literature-anchored findings (GeneRIF, showing 12)

• IHPK2 over expression enhances sensitivity of ovarian carcinoma cells to radiation, IFN-beta, caspase 8 and DR4 (PMID:11896621)
• InsP6K2 is a physiologic mediator of cell death (PMID:15533939)
• IHPK2-TRAF2 binding leads to attenuation of TAK1- and NF-kappaB-mediated signaling and is partially responsible for the apoptotic activity of IHPK2. (PMID:17379600)
• Gene disruption of IP6K2 in colorectal cancer cells selectively impairs p53-mediated apoptosis, instead favoring cell-cycle arrest. IP6K2 acts by binding directly to p53 and decreasing expression of proarrest gene targets (PMID:21078964)
• Casein kinase-2 mediates cell survival through phosphorylation and degradation of inositol hexakisphosphate kinase-2. (PMID:21262846)
• Genetic polymorphisms in IP6K2 gene is associated with autoimmune disease. (PMID:22446964)
• FGF2-signaling involves the inositol polyphosphate cascade, including inositol hexakisphosphate kinase (IP6K), and demonstrate that IP6K1,2 regulates Runx2 and osteoblast gene expression. (PMID:23322705)
• An alpha-helical pair and a rare, two-turn 310 helix, that together form a substrate-binding pocket of IP6K2. (PMID:24956979)
• conclude that IP6K1 and -2 together control inositol pyrophosphate metabolism and thereby physiologically regulate phosphate export and other aspects of mammalian cellular phosphate homeostasis (PMID:31186349)
• LINC00467 knockdown repressed cell proliferation but stimulated cell apoptosis in glioblastoma via miR-339-3p/IP6K2 axis. (PMID:32176627)
• Inositol hexakisphosphate kinase 2 promotes cell death of anterior horn cells in the spinal cord of patients with amyotrophic lateral sclerosis. (PMID:32929655)
• Circ-IP6K2 suppresses tumor progression by modulating the miR-1292-5p/CAMK2N1 signal in clear cell renal cell carcinoma. (PMID:38980439)

Cross-species orthologs

8 orthologs

Organism	Symbol	Gene ID
danio_rerio	ip6k2a	ENSDARG00000008310
danio_rerio	ip6k2b	ENSDARG00000019613
mus_musculus	Ip6k2	ENSMUSG00000032599
rattus_norvegicus	Ip6k2	ENSRNOG00000020361
drosophila_melanogaster	IP3K1	FBGN0032147
drosophila_melanogaster	Ip6k	FBGN0034644
caenorhabditis_elegans	lfe-2	WBGENE00002979
caenorhabditis_elegans	F30A10.3	WBGENE00009262

Paralogs (6): ITPKC (ENSG00000086544), ITPKA (ENSG00000137825), ITPKB (ENSG00000143772), IPMK (ENSG00000151151), IP6K3 (ENSG00000161896), IP6K1 (ENSG00000176095)

Protein

Protein identifiers

Inositol hexakisphosphate kinase 2 — Q9UHH9 (reviewed: Q9UHH9)

Alternative names: P(i)-uptake stimulator

All UniProt accessions (15): Q9UHH9, B2RCP4, C9J124, C9J3W9, C9J536, C9J790, C9J8W6, C9JGK2, C9JHV2, C9JHX0, C9JLG7, C9JMC9, C9JRM0, C9JU99, F8WDQ5

UniProt curated annotations — full annotation on UniProt →

Function. Converts inositol hexakisphosphate (InsP6) to diphosphoinositol pentakisphosphate (InsP7/PP-InsP5).

Subcellular location. Nucleus.

Activity regulation. Inhibited by flavonoids, including myricetin, quercetin, luteolin, isorhamnetin, rhamnetin, kaempferol, diosmetin and apigenin.

Pathway. Phospholipid metabolism; phosphatidylinositol metabolism.

Miscellaneous. May be produced at very low levels due to a premature stop codon in the mRNA, leading to nonsense-mediated mRNA decay.

Similarity. Belongs to the inositol phosphokinase (IPK) family.

Isoforms (6)

UniProt ID	Names	Canonical?
Q9UHH9-1	1	yes
Q9UHH9-2	2
Q9UHH9-3	3
Q9UHH9-4	4
Q9UHH9-5	5
Q9UHH9-6	6

RefSeq proteins (8): NP_001005909, NP_001005910, NP_001005911, NP_001139650, NP_001139651, NP_001177245, NP_001177246, NP_057375* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR005522	IPK	Family
IPR038286	IPK_sf	Homologous_superfamily

Pfam: PF03770

Enzyme classification (BRENDA):

• EC 2.7.4.21 — inositol-hexakisphosphate 5-kinase (BRENDA: 10 organisms, 35 substrates, 31 inhibitors, 11 Km, 1 kcat entries)

Substrate kinetics (BRENDA)

6 substrates with measured Km, best-characterized 6. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
ATP	0.037–1.4	4
INOSITOL HEXAKISPHOSPHATE	0.0007–0.0061	3
1D-MYO-INOSITOL HEXAKISPHOSPHATE	0.0004	1
5-DIPHOSPHO-1D-MYO-INOSITOL (1,2,3,4,6)PENTAKISP	0.002	1
ADP	1.57	1
D-MYO-INOSITOL-1,3,4,5,6-PENTAKISPHOSPHATE	0.0055	1

Catalyzed reactions (Rhea), 1 shown:

• 1D-myo-inositol hexakisphosphate + ATP = 5-diphospho-1D-myo-inositol 1,2,3,4,6-pentakisphosphate + ADP (RHEA:12793)

UniProt features (19 total): splice variant 10, binding site 6, sequence conflict 2, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9UHH9-F1	75.92	0.50

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (6): 207–209; 220; 222; 236–243; 383; 386

Function

Pathways and Gene Ontology

Reactome pathways

7 pathways

ID	Pathway
R-HSA-1855191	Synthesis of IPs in the nucleus
R-HSA-909733	Interferon alpha/beta signaling
R-HSA-1280215	Cytokine Signaling in Immune system
R-HSA-1430728	Metabolism
R-HSA-1483249	Inositol phosphate metabolism
R-HSA-168256	Immune System
R-HSA-913531	Interferon Signaling

MSigDB gene sets: 244 (showing top): AHRARNT_01, GOBP_PHOSPHOLIPID_METABOLIC_PROCESS, GOBP_PHOSPHATIDYLINOSITOL_METABOLIC_PROCESS, GOBP_REGULATION_OF_PHOSPHORYLATION, REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM, RORA1_01, ATACCTC_MIR202, GOBP_NEGATIVE_REGULATION_OF_CELL_GROWTH, GOBP_INOSITOL_PHOSPHATE_METABOLIC_PROCESS, GOBP_PEPTIDYL_SERINE_MODIFICATION, GOBP_POLYOL_METABOLIC_PROCESS, GOBP_GROWTH, GOBP_REGULATION_OF_TRANSFERASE_ACTIVITY, GOBP_ORGANOPHOSPHATE_METABOLIC_PROCESS, AAAYRNCTG_UNKNOWN

GO Biological Process (11): negative regulation of cell growth (GO:0030308), inositol phosphate biosynthetic process (GO:0032958), positive regulation of apoptotic process (GO:0043065), inositol phosphate metabolic process (GO:0043647), phosphatidylinositol phosphate biosynthetic process (GO:0046854), protein stabilization (GO:0050821), positive regulation of protein K48-linked ubiquitination (GO:1902524), cellular response to flavonoid (GO:1905396), lipid metabolic process (GO:0006629), phosphatidylinositol metabolic process (GO:0046488), organophosphate biosynthetic process (GO:0090407)

GO Molecular Function (13): inositol-1,3,4,5,6-pentakisphosphate kinase activity (GO:0000827), inositol hexakisphosphate kinase activity (GO:0000828), diphosphoinositol pentakisphosphate kinase activity (GO:0000829), inositol hexakisphosphate 5-kinase activity (GO:0000832), ATP binding (GO:0005524), protein-containing complex binding (GO:0044877), inositol 5-diphosphate pentakisphosphate 5-kinase activity (GO:0052836), diphosphoinositol tetrakisphosphate kinase activity (GO:0052839), flavonoid binding (GO:0097243), nucleotide binding (GO:0000166), protein binding (GO:0005515), kinase activity (GO:0016301), transferase activity (GO:0016740)

GO Cellular Component (5): fibrillar center (GO:0001650), nucleus (GO:0005634), nucleoplasm (GO:0005654), cytoplasm (GO:0005737), cell junction (GO:0030054)

Reactome top-level categories

Rollup of top-5 pathways:

Category	Pathways
Inositol phosphate metabolism	1
Interferon Signaling	1
Immune System	1
Metabolism	1
Cytokine Signaling in Immune system	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
inositol phosphate kinase activity	5
cellular anatomical structure	4
phosphotransferase activity, phosphate group as acceptor	3
binding	3
organophosphate metabolic process	2
phosphotransferase activity, alcohol group as acceptor	2
regulation of cell growth	1
cell growth	1
negative regulation of growth	1
negative regulation of cellular process	1
inositol phosphate metabolic process	1
polyol biosynthetic process	1
organophosphate biosynthetic process	1
apoptotic process	1
regulation of apoptotic process	1
positive regulation of programmed cell death	1
polyol metabolic process	1
glycerophospholipid biosynthetic process	1
regulation of protein stability	1
regulation of protein K48-linked ubiquitination	1
protein K48-linked ubiquitination	1
positive regulation of protein polyubiquitination	1
cellular response to oxygen-containing compound	1
response to flavonoid	1
primary metabolic process	1
phosphorus metabolic process	1
biosynthetic process	1
inositol hexakisphosphate kinase activity	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
transferase activity, transferring phosphorus-containing groups	1
catalytic activity	1
nucleolus	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

946 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
IP6K2	PPIP5K1	Q6PFW1	937
IP6K2	PPIP5K2	O43314	879
IP6K2	POLR1F	Q3B726	773
IP6K2	DUSP16	Q9BY84	701
IP6K2	FKBP4	Q02790	695
IP6K2	ITPKB	P27987	670
IP6K2	ITPKA	P23677	651
IP6K2	IPPK	Q9H8X2	611
IP6K2	EXT2	Q93063	600
IP6K2	HSP90AA1	P07900	559
IP6K2	FKBP8	Q14318	493
IP6K2	NKX2-1	P43699	491
IP6K2	CCDC106	Q9BWC9	476
IP6K2	LNX2	Q8N448	474
IP6K2	CDC37	Q16543	460

IntAct

29 interactions, top by confidence:

A	B	Type	Score
IP6K2	LNX2	psi-mi:“MI:0915”(physical association)	0.670
LNX2	IP6K2	psi-mi:“MI:0915”(physical association)	0.670
IP6K2	TP53	psi-mi:“MI:0407”(direct interaction)	0.600
IP6K2	TP53	psi-mi:“MI:0915”(physical association)	0.600
IP6K2	MEOX2	psi-mi:“MI:0915”(physical association)	0.560
RBPMS	IP6K2	psi-mi:“MI:0915”(physical association)	0.560
MEOX2	IP6K2	psi-mi:“MI:0915”(physical association)	0.560
IP6K2	RBPMS	psi-mi:“MI:0915”(physical association)	0.560
HSP90AA1	IP6K2	psi-mi:“MI:0407”(direct interaction)	0.560
IP6K2	PGK2	psi-mi:“MI:0914”(association)	0.560
PLOD3	IP6K2	psi-mi:“MI:0915”(physical association)	0.560
ZBTB2	IP6K2	psi-mi:“MI:0915”(physical association)	0.560
IP6K2	PGK2	psi-mi:“MI:0915”(physical association)	0.560
IP6K2		psi-mi:“MI:0915”(physical association)	0.400
IP6K2	CCT6A	psi-mi:“MI:0915”(physical association)	0.400
IP6K2	IP6K1	psi-mi:“MI:0915”(physical association)	0.400
IP6K2		psi-mi:“MI:0915”(physical association)	0.370
PLSCR1	IP6K2	psi-mi:“MI:0915”(physical association)	0.370
IP6K2	ZBTB2	psi-mi:“MI:0915”(physical association)	0.000
PLOD3	IP6K2	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (24): IP6K2 (Two-hybrid), IP6K2 (Two-hybrid), GTPBP6 (Affinity Capture-MS), IP6K2 (Two-hybrid), IP6K2 (Affinity Capture-RNA), IP6K2 (Two-hybrid), PGK2 (Affinity Capture-MS), RHOU (Affinity Capture-MS), IP6K2 (Affinity Capture-RNA), IP6K2 (Two-hybrid), PLOD3 (Two-hybrid), ZBTB2 (Two-hybrid), IP6K2 (Proximity Label-MS), IP6K2 (Affinity Capture-RNA), PGK2 (Affinity Capture-MS)

ESM2 similar proteins: A7MBL8, B3EX61, G3V7Q0, O00763, O02810, O13010, O60942, O70172, O88370, O88377, O94806, P10687, P10894, P48426, P69341, P78356, P97789, Q0P5F7, Q13613, Q15139, Q15147, Q5F356, Q5PQ01, Q5R488, Q6DIX1, Q6GL14, Q6IQ26, Q6IQE1, Q6PAL8, Q7TT16, Q80V72, Q80XI4, Q8BKC8, Q8BPM2, Q8BWW9, Q8IZH2, Q8K1Y2, Q8NFU5, Q8TBX8, Q91XU3

Diamond homologs: O74561, Q12494, Q6PD10, Q80V72, Q8BWD2, Q92551, Q95221, Q96PC2, Q9ESM0, Q9R0U1, Q9UHH9, A2X5H5, Q6H545, Q7TT16, Q8NFU5, Q99NI4, Q9US14, P07250

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
CSNK2A1	“down-regulates quantity by destabilization”	IP6K2	phosphorylation

Disease & clinical

Clinical variants and AI predictions

ClinVar

55 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	39
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1618 predictions. Top by Δscore:

Variant	Effect	Δscore
3:48688769:TACAC:T	acceptor_gain	1.0000
3:48688770:ACAC:A	acceptor_gain	1.0000
3:48688771:CAC:C	acceptor_gain	1.0000
3:48688771:CACC:C	acceptor_gain	1.0000
3:48688772:AC:A	acceptor_gain	1.0000
3:48688772:ACC:A	acceptor_loss	1.0000
3:48688773:CCTG:C	acceptor_gain	1.0000
3:48688774:C:CC	acceptor_gain	1.0000
3:48688775:T:C	acceptor_loss	1.0000
3:48689701:A:T	acceptor_gain	1.0000
3:48691310:A:AC	donor_gain	1.0000
3:48691311:C:CC	donor_gain	1.0000
3:48691483:C:CC	acceptor_gain	1.0000
3:48692949:CTCA:C	donor_loss	1.0000
3:48692950:TCACC:T	donor_loss	1.0000
3:48692951:CACCT:C	donor_loss	1.0000
3:48692952:ACC:A	donor_loss	1.0000
3:48692953:CCT:C	donor_gain	1.0000
3:48693177:CAC:C	acceptor_gain	1.0000
3:48693178:ACCT:A	acceptor_loss	1.0000
3:48693180:C:CC	acceptor_gain	1.0000
3:48693180:CTGGA:C	acceptor_loss	1.0000
3:48693190:G:C	acceptor_gain	1.0000
3:48695085:CTTA:C	donor_loss	1.0000
3:48695086:TTA:T	donor_loss	1.0000
3:48695087:TA:T	donor_loss	1.0000
3:48695088:A:AC	donor_gain	1.0000
3:48695089:C:CC	donor_gain	1.0000
3:48695089:C:CT	donor_loss	1.0000
3:48695417:CTCTG:C	acceptor_gain	1.0000

AlphaMissense

2819 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:48688316:A:G	L413P	1.000
3:48688325:A:G	L410P	1.000
3:48688328:C:T	G409E	1.000
3:48688329:C:A	G409W	1.000
3:48688329:C:G	G409R	1.000
3:48688329:C:T	G409R	1.000
3:48688347:C:G	D403H	1.000
3:48688402:A:C	F384L	1.000
3:48688402:A:T	F384L	1.000
3:48688404:A:G	F384L	1.000
3:48688405:G:C	D383E	1.000
3:48688405:G:T	D383E	1.000
3:48688406:T:A	D383V	1.000
3:48688406:T:C	D383G	1.000
3:48688406:T:G	D383A	1.000
3:48688407:C:G	D383H	1.000
3:48688415:C:G	R380P	1.000
3:48688559:A:G	L332P	1.000
3:48688562:A:G	L331P	1.000
3:48688567:G:C	S329R	1.000
3:48688567:G:T	S329R	1.000
3:48688569:T:G	S329R	1.000
3:48688580:C:G	R325P	1.000
3:48688581:G:T	R325S	1.000
3:48688613:A:G	L314P	1.000
3:48688622:A:G	L311P	1.000
3:48688678:G:C	F292L	1.000
3:48688678:G:T	F292L	1.000
3:48688680:A:G	F292L	1.000
3:48688721:C:G	R278P	1.000

dbSNP variants (sampled 300 via entrez): RS1000036948 (3:48711108 G>A), RS1000107236 (3:48704045 T>C), RS1000149928 (3:48717731 G>A,T), RS1000227203 (3:48716040 T>C), RS1000475268 (3:48689559 A>G), RS1000594149 (3:48712359 C>T), RS1000608125 (3:48718083 G>A), RS1000744442 (3:48706266 C>T), RS1000764700 (3:48689935 G>A), RS1000802885 (3:48706616 G>C), RS1000865690 (3:48705304 G>A), RS1000893090 (3:48702661 G>GTGT), RS1000943169 (3:48716794 G>A), RS1000957470 (3:48693615 G>A,C), RS1001046407 (3:48712656 T>C)

Disease associations

OMIM: gene MIM:606992 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

28 associations (top):

Study	Trait	p-value
GCST001725_77	Inflammatory bowel disease	1.000000e-47
GCST002548_9	Ulcerative colitis	8.000000e-07
GCST002774_5	Cognitive function	3.000000e-06
GCST004131_23	Inflammatory bowel disease	1.000000e-33
GCST004132_17	Crohn’s disease	3.000000e-23
GCST004133_11	Ulcerative colitis	8.000000e-20
GCST006269_813	General cognitive ability	9.000000e-09
GCST006611_70	HDL cholesterol	7.000000e-09
GCST006944_33	Experiencing mood swings	4.000000e-09
GCST006947_44	Feeling fed-up	1.000000e-10
GCST007094_111	Diastolic blood pressure	2.000000e-08
GCST007565_146	Morning person	6.000000e-17
GCST009325_92	Parkinson’s disease or first degree relation to individual with Parkinson’s disease	1.000000e-10
GCST009524_287	Household income (MTAG)	4.000000e-09
GCST009524_340	Household income (MTAG)	6.000000e-13
GCST010002_422	Refractive error	4.000000e-14
GCST010698_80	Subcortical volume (min-P)	3.000000e-24
GCST010699_110	Brain morphology (min-P)	4.000000e-08
GCST010701_52	Cortical surface area (MOSTest)	1.000000e-16
GCST010702_36	Subcortical volume (MOSTest)	1.000000e-10
GCST010703_262	Brain morphology (MOSTest)	2.000000e-13
GCST010988_141	Adult body size	7.000000e-14
GCST012226_606	Waist circumference adjusted for body mass index	3.000000e-12
GCST012226_608	Waist circumference adjusted for body mass index	8.000000e-09
GCST012232_6	Lipoprotein (a) levels	5.000000e-09
GCST90000050_21	Age at first birth	9.000000e-19
GCST90002381_148	Eosinophil count	1.000000e-13
GCST90020029_1174	Waist circumference adjusted for body mass index	1.000000e-08

EFO canonical traits (12, from GWAS)

EFO ID	Trait name
EFO:0004337	intelligence
EFO:0004612	high density lipoprotein cholesterol measurement
EFO:0008475	mood instability measurement
EFO:0009588	feeling “fed-up” measurement
EFO:0006336	diastolic blood pressure
EFO:0008328	chronotype measurement
EFO:0009695	household income
EFO:0004346	neuroimaging measurement
EFO:0007789	BMI-adjusted waist circumference
EFO:0006925	lipoprotein A measurement
EFO:0009101	age at first birth measurement
EFO:0004842	eosinophil count

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4523488 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

3 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 124,022 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL50	QUERCETIN	3	74,559
CHEMBL151	LUTEOLIN	2	23,523
CHEMBL150	KAEMPFEROL	1	25,940

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB variants

2 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs3172494	IP6K2		0.00	0
rs61740999	IP6K2		0.00	0

ChEMBL bioactivities

49 potent at pChembl≥5 of 62 total, top 49 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.31	IC50	4.9	nM	CHEMBL5190343
7.60	IC50	25	nM	CHEMBL5203174
7.27	IC50	54	nM	CHEMBL5169462
7.19	IC50	65	nM	CHEMBL5186210
7.15	IC50	71	nM	CHEMBL5200214
7.13	IC50	74	nM	CHEMBL5181623
7.13	Kd	74	nM	CHEMBL5190343
7.03	IC50	94	nM	CHEMBL5184960
7.03	IC50	94	nM	CHEMBL5190343
7.00	IC50	100	nM	CHEMBL5204881
6.89	IC50	130	nM	CHEMBL5184940
6.89	IC50	130	nM	CHEMBL5196483
6.82	IC50	150	nM	CHEMBL5201078
6.82	IC50	150	nM	CHEMBL5186729
6.72	IC50	190	nM	CHEMBL5197626
6.62	IC50	240	nM	CHEMBL5175579
6.55	IC50	280	nM	CHEMBL1460920
6.55	IC50	280	nM	CHEMBL5185725
6.54	IC50	290	nM	CHEMBL5190846
6.50	IC50	320	nM	CHEMBL5201056
6.46	IC50	350	nM	CHEMBL5198845
6.39	IC50	410	nM	CHEMBL5189856
6.36	IC50	440	nM	CHEMBL1379963
6.32	IC50	480	nM	CHEMBL5188320
6.30	IC50	500	nM	ISORHAMNETIN
6.24	IC50	580	nM	CHEMBL1485263
6.24	IC50	580	nM	CHEMBL5171388
6.19	IC50	650	nM	CHEMBL5192487
6.16	IC50	700	nM	MYRICETIN
6.16	IC50	700	nM	QUERCETIN
6.16	IC50	690	nM	CHEMBL5203362
6.14	IC50	720	nM	CHEMBL5185229
6.09	IC50	820	nM	CHEMBL5206215
6.05	IC50	900	nM	DIOSMETIN
5.92	IC50	1190	nM	CHEMBL5195827
5.89	IC50	1300	nM	LUTEOLIN
5.84	IC50	1460	nM	CHEMBL5205377
5.80	IC50	1580	nM	CHEMBL5178065
5.75	IC50	1800	nM	RHAMNETIN
5.70	IC50	2000	nM	CHEMBL467591
5.67	IC50	2120	nM	CHEMBL5209246
5.62	IC50	2390	nM	CHEMBL5178548
5.60	IC50	2500	nM	KAEMPFEROL
5.31	Ki	4880	nM	CHEMBL4555782
5.24	IC50	5700	nM	ACACETIN
5.19	IC50	6510	nM	CHEMBL5199101
5.15	IC50	7100	nM	APIGENIN
5.10	IC50	8000	nM	CHEMBL243677
5.06	IC50	8650	nM	CHEMBL1368139

PubChem BioAssay actives

49 with measured affinity, of 89 total; 47 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
3-(4-phenylphenyl)-2,1-benzoxazole-5-carboxylic acid	1909478: Inhibition of N-terminal 6His-tagged/TEV cleavage site fused recombinant human IP6K2 expressed in Escherichia coli assessed as inhibition of [3H]-InsP6 phosphorylation measured after 180 mins by HPLC analysis	ic50	0.0049	uM
1’-(4-chlorobenzoyl)-2-oxospiro[1H-indole-3,4’-piperidine]-5-carboxylic acid	1909472: Inhibition of recombinant full length human IP6K2 assessed as inorganic phosphate release measured after 30 mins by ADP-Glo Max assay	ic50	0.0250	uM
3-(4-pyridin-3-ylphenyl)-2,1-benzoxazole-5-carboxylic acid	1909469: Inhibition of N-terminal 6His-tagged/TEV cleavage site fused recombinant human IP6K2 expressed in Escherichia coli assessed as inorganic phosphate release using InsP6 as substrate in presence of ATP measured after 60 to 120 mins by malachite green based colorimetric - DIPP1 coupled enzyme assay	ic50	0.0540	uM
3-(4-benzylphenyl)-2,1-benzoxazole-5-carboxylic acid	1909469: Inhibition of N-terminal 6His-tagged/TEV cleavage site fused recombinant human IP6K2 expressed in Escherichia coli assessed as inorganic phosphate release using InsP6 as substrate in presence of ATP measured after 60 to 120 mins by malachite green based colorimetric - DIPP1 coupled enzyme assay	ic50	0.0650	uM
3-[3-[(3,5-dichloro-2-pyridinyl)oxy]phenyl]-2,1-benzoxazole-5-carboxylic acid	1909469: Inhibition of N-terminal 6His-tagged/TEV cleavage site fused recombinant human IP6K2 expressed in Escherichia coli assessed as inorganic phosphate release using InsP6 as substrate in presence of ATP measured after 60 to 120 mins by malachite green based colorimetric - DIPP1 coupled enzyme assay	ic50	0.0710	uM
(E)-3-[3-(4-phenylphenyl)-2,1-benzoxazol-5-yl]prop-2-enoic acid	1909469: Inhibition of N-terminal 6His-tagged/TEV cleavage site fused recombinant human IP6K2 expressed in Escherichia coli assessed as inorganic phosphate release using InsP6 as substrate in presence of ATP measured after 60 to 120 mins by malachite green based colorimetric - DIPP1 coupled enzyme assay	ic50	0.0740	uM
(E)-3-[3-(4-phenoxyphenyl)-2,1-benzoxazol-5-yl]prop-2-enoic acid	1909469: Inhibition of N-terminal 6His-tagged/TEV cleavage site fused recombinant human IP6K2 expressed in Escherichia coli assessed as inorganic phosphate release using InsP6 as substrate in presence of ATP measured after 60 to 120 mins by malachite green based colorimetric - DIPP1 coupled enzyme assay	ic50	0.0940	uM
3-(3,5-dimethylphenyl)-2,1-benzoxazole-5-carboxylic acid	1909469: Inhibition of N-terminal 6His-tagged/TEV cleavage site fused recombinant human IP6K2 expressed in Escherichia coli assessed as inorganic phosphate release using InsP6 as substrate in presence of ATP measured after 60 to 120 mins by malachite green based colorimetric - DIPP1 coupled enzyme assay	ic50	0.1000	uM
3-(3-phenylphenyl)-2,1-benzoxazole-5-carboxylic acid	1909469: Inhibition of N-terminal 6His-tagged/TEV cleavage site fused recombinant human IP6K2 expressed in Escherichia coli assessed as inorganic phosphate release using InsP6 as substrate in presence of ATP measured after 60 to 120 mins by malachite green based colorimetric - DIPP1 coupled enzyme assay	ic50	0.1300	uM
3-(3-phenoxyphenyl)-2,1-benzoxazole-5-carboxylic acid	1909469: Inhibition of N-terminal 6His-tagged/TEV cleavage site fused recombinant human IP6K2 expressed in Escherichia coli assessed as inorganic phosphate release using InsP6 as substrate in presence of ATP measured after 60 to 120 mins by malachite green based colorimetric - DIPP1 coupled enzyme assay	ic50	0.1300	uM
3-(3-methylphenyl)-2,1-benzoxazole-5-carboxylic acid	1909469: Inhibition of N-terminal 6His-tagged/TEV cleavage site fused recombinant human IP6K2 expressed in Escherichia coli assessed as inorganic phosphate release using InsP6 as substrate in presence of ATP measured after 60 to 120 mins by malachite green based colorimetric - DIPP1 coupled enzyme assay	ic50	0.1500	uM
3-(4-pyridin-4-ylphenyl)-2,1-benzoxazole-5-carboxylic acid	1909469: Inhibition of N-terminal 6His-tagged/TEV cleavage site fused recombinant human IP6K2 expressed in Escherichia coli assessed as inorganic phosphate release using InsP6 as substrate in presence of ATP measured after 60 to 120 mins by malachite green based colorimetric - DIPP1 coupled enzyme assay	ic50	0.1500	uM
3-[4-(cyclopentanecarbonylamino)phenyl]-2,1-benzoxazole-5-carboxylic acid	1909469: Inhibition of N-terminal 6His-tagged/TEV cleavage site fused recombinant human IP6K2 expressed in Escherichia coli assessed as inorganic phosphate release using InsP6 as substrate in presence of ATP measured after 60 to 120 mins by malachite green based colorimetric - DIPP1 coupled enzyme assay	ic50	0.1900	uM
3-(4-piperidin-1-ylphenyl)-2,1-benzoxazole-5-carboxylic acid	1909469: Inhibition of N-terminal 6His-tagged/TEV cleavage site fused recombinant human IP6K2 expressed in Escherichia coli assessed as inorganic phosphate release using InsP6 as substrate in presence of ATP measured after 60 to 120 mins by malachite green based colorimetric - DIPP1 coupled enzyme assay	ic50	0.2400	uM
3-(4-phenoxyphenyl)-2,1-benzoxazole-5-carboxylic acid	1909469: Inhibition of N-terminal 6His-tagged/TEV cleavage site fused recombinant human IP6K2 expressed in Escherichia coli assessed as inorganic phosphate release using InsP6 as substrate in presence of ATP measured after 60 to 120 mins by malachite green based colorimetric - DIPP1 coupled enzyme assay	ic50	0.2800	uM
3-phenyl-2,1-benzoxazole-5-carboxylic acid	1909469: Inhibition of N-terminal 6His-tagged/TEV cleavage site fused recombinant human IP6K2 expressed in Escherichia coli assessed as inorganic phosphate release using InsP6 as substrate in presence of ATP measured after 60 to 120 mins by malachite green based colorimetric - DIPP1 coupled enzyme assay	ic50	0.2800	uM
(E)-3-[3-(3-methylphenyl)-2,1-benzoxazol-5-yl]prop-2-enoic acid	1909469: Inhibition of N-terminal 6His-tagged/TEV cleavage site fused recombinant human IP6K2 expressed in Escherichia coli assessed as inorganic phosphate release using InsP6 as substrate in presence of ATP measured after 60 to 120 mins by malachite green based colorimetric - DIPP1 coupled enzyme assay	ic50	0.2900	uM
(E)-3-[3-[4-(trifluoromethoxy)phenyl]-2,1-benzoxazol-5-yl]prop-2-enoic acid	1909469: Inhibition of N-terminal 6His-tagged/TEV cleavage site fused recombinant human IP6K2 expressed in Escherichia coli assessed as inorganic phosphate release using InsP6 as substrate in presence of ATP measured after 60 to 120 mins by malachite green based colorimetric - DIPP1 coupled enzyme assay	ic50	0.3200	uM
3-[4-(propan-2-ylcarbamoyl)phenyl]-2,1-benzoxazole-5-carboxylic acid	1909469: Inhibition of N-terminal 6His-tagged/TEV cleavage site fused recombinant human IP6K2 expressed in Escherichia coli assessed as inorganic phosphate release using InsP6 as substrate in presence of ATP measured after 60 to 120 mins by malachite green based colorimetric - DIPP1 coupled enzyme assay	ic50	0.3500	uM
3-[3-(cyclopropanecarbonylamino)phenyl]-2,1-benzoxazole-5-carboxylic acid	1909469: Inhibition of N-terminal 6His-tagged/TEV cleavage site fused recombinant human IP6K2 expressed in Escherichia coli assessed as inorganic phosphate release using InsP6 as substrate in presence of ATP measured after 60 to 120 mins by malachite green based colorimetric - DIPP1 coupled enzyme assay	ic50	0.4100	uM
3-(4-methylphenyl)-2,1-benzoxazole-5-carboxylic acid	1909469: Inhibition of N-terminal 6His-tagged/TEV cleavage site fused recombinant human IP6K2 expressed in Escherichia coli assessed as inorganic phosphate release using InsP6 as substrate in presence of ATP measured after 60 to 120 mins by malachite green based colorimetric - DIPP1 coupled enzyme assay	ic50	0.4400	uM
3-[4-(2-oxopyrrolidin-1-yl)phenyl]-2,1-benzoxazole-5-carboxylic acid	1909469: Inhibition of N-terminal 6His-tagged/TEV cleavage site fused recombinant human IP6K2 expressed in Escherichia coli assessed as inorganic phosphate release using InsP6 as substrate in presence of ATP measured after 60 to 120 mins by malachite green based colorimetric - DIPP1 coupled enzyme assay	ic50	0.4800	uM
3,5,7-trihydroxy-2-(4-hydroxy-3-methoxyphenyl)chromen-4-one	1572024: Inhibition of human IP6K2 using insP6 as substrate preincubated for 15 mins followed by substrate and measured after 30 mins by TR-FRET assay	ic50	0.5000	uM
3-(4-benzamidophenyl)-2,1-benzoxazole-5-carboxylic acid	1909469: Inhibition of N-terminal 6His-tagged/TEV cleavage site fused recombinant human IP6K2 expressed in Escherichia coli assessed as inorganic phosphate release using InsP6 as substrate in presence of ATP measured after 60 to 120 mins by malachite green based colorimetric - DIPP1 coupled enzyme assay	ic50	0.5800	uM
(E)-3-(3-phenyl-2,1-benzoxazol-6-yl)prop-2-enoic acid	1909469: Inhibition of N-terminal 6His-tagged/TEV cleavage site fused recombinant human IP6K2 expressed in Escherichia coli assessed as inorganic phosphate release using InsP6 as substrate in presence of ATP measured after 60 to 120 mins by malachite green based colorimetric - DIPP1 coupled enzyme assay	ic50	0.5800	uM
3-[4-[(3,5-dichloro-2-pyridinyl)oxy]phenyl]-2,1-benzoxazole-5-carboxylic acid	1909469: Inhibition of N-terminal 6His-tagged/TEV cleavage site fused recombinant human IP6K2 expressed in Escherichia coli assessed as inorganic phosphate release using InsP6 as substrate in presence of ATP measured after 60 to 120 mins by malachite green based colorimetric - DIPP1 coupled enzyme assay	ic50	0.6500	uM
3-(3-pyridin-2-yloxyphenyl)-2,1-benzoxazole-5-carboxylic acid	1909469: Inhibition of N-terminal 6His-tagged/TEV cleavage site fused recombinant human IP6K2 expressed in Escherichia coli assessed as inorganic phosphate release using InsP6 as substrate in presence of ATP measured after 60 to 120 mins by malachite green based colorimetric - DIPP1 coupled enzyme assay	ic50	0.6900	uM
Quercetin	1572024: Inhibition of human IP6K2 using insP6 as substrate preincubated for 15 mins followed by substrate and measured after 30 mins by TR-FRET assay	ic50	0.7000	uM
3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)chromen-4-one	1572024: Inhibition of human IP6K2 using insP6 as substrate preincubated for 15 mins followed by substrate and measured after 30 mins by TR-FRET assay	ic50	0.7000	uM
3-[4-(pyrimidine-4-carbonylamino)phenyl]-2,1-benzoxazole-5-carboxylic acid	1909469: Inhibition of N-terminal 6His-tagged/TEV cleavage site fused recombinant human IP6K2 expressed in Escherichia coli assessed as inorganic phosphate release using InsP6 as substrate in presence of ATP measured after 60 to 120 mins by malachite green based colorimetric - DIPP1 coupled enzyme assay	ic50	0.7200	uM
3-[4-(2-methylpropanoylamino)phenyl]-2,1-benzoxazole-5-carboxylic acid	1909469: Inhibition of N-terminal 6His-tagged/TEV cleavage site fused recombinant human IP6K2 expressed in Escherichia coli assessed as inorganic phosphate release using InsP6 as substrate in presence of ATP measured after 60 to 120 mins by malachite green based colorimetric - DIPP1 coupled enzyme assay	ic50	0.8200	uM
Diosmetin	1572024: Inhibition of human IP6K2 using insP6 as substrate preincubated for 15 mins followed by substrate and measured after 30 mins by TR-FRET assay	ic50	0.9000	uM
3-(4-pyridin-2-yloxyphenyl)-2,1-benzoxazole-5-carboxylic acid	1909469: Inhibition of N-terminal 6His-tagged/TEV cleavage site fused recombinant human IP6K2 expressed in Escherichia coli assessed as inorganic phosphate release using InsP6 as substrate in presence of ATP measured after 60 to 120 mins by malachite green based colorimetric - DIPP1 coupled enzyme assay	ic50	1.1900	uM
2-(3,4-dihydroxyphenyl)-5,7-dihydroxychromen-4-one	1572024: Inhibition of human IP6K2 using insP6 as substrate preincubated for 15 mins followed by substrate and measured after 30 mins by TR-FRET assay	ic50	1.3000	uM
3-[3-(trifluoromethyl)phenyl]-2,1-benzoxazole-5-carboxylic acid	1909469: Inhibition of N-terminal 6His-tagged/TEV cleavage site fused recombinant human IP6K2 expressed in Escherichia coli assessed as inorganic phosphate release using InsP6 as substrate in presence of ATP measured after 60 to 120 mins by malachite green based colorimetric - DIPP1 coupled enzyme assay	ic50	1.4600	uM
methyl (E)-3-(3-phenyl-2,1-benzoxazol-5-yl)prop-2-enoate	1909469: Inhibition of N-terminal 6His-tagged/TEV cleavage site fused recombinant human IP6K2 expressed in Escherichia coli assessed as inorganic phosphate release using InsP6 as substrate in presence of ATP measured after 60 to 120 mins by malachite green based colorimetric - DIPP1 coupled enzyme assay	ic50	1.5800	uM
2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-7-methoxychromen-4-one	1572024: Inhibition of human IP6K2 using insP6 as substrate preincubated for 15 mins followed by substrate and measured after 30 mins by TR-FRET assay	ic50	1.8000	uM
6-N-[(4-nitrophenyl)methyl]-2-N-[[3-(trifluoromethyl)phenyl]methyl]-7H-purine-2,6-diamine	1909469: Inhibition of N-terminal 6His-tagged/TEV cleavage site fused recombinant human IP6K2 expressed in Escherichia coli assessed as inorganic phosphate release using InsP6 as substrate in presence of ATP measured after 60 to 120 mins by malachite green based colorimetric - DIPP1 coupled enzyme assay	ic50	2.0000	uM
N-methyl-3-phenyl-2,1-benzoxazole-5-carboxamide	1909469: Inhibition of N-terminal 6His-tagged/TEV cleavage site fused recombinant human IP6K2 expressed in Escherichia coli assessed as inorganic phosphate release using InsP6 as substrate in presence of ATP measured after 60 to 120 mins by malachite green based colorimetric - DIPP1 coupled enzyme assay	ic50	2.1200	uM
3-[4-[(6-oxopiperidine-3-carbonyl)amino]phenyl]-2,1-benzoxazole-5-carboxylic acid	1909469: Inhibition of N-terminal 6His-tagged/TEV cleavage site fused recombinant human IP6K2 expressed in Escherichia coli assessed as inorganic phosphate release using InsP6 as substrate in presence of ATP measured after 60 to 120 mins by malachite green based colorimetric - DIPP1 coupled enzyme assay	ic50	2.3900	uM
3,5,7-trihydroxy-2-(4-hydroxyphenyl)chromen-4-one	1572024: Inhibition of human IP6K2 using insP6 as substrate preincubated for 15 mins followed by substrate and measured after 30 mins by TR-FRET assay	ic50	2.5000	uM
5-[[[2-[2-(6-methoxy-1H-indol-3-yl)ethylamino]-7H-purin-6-yl]amino]methyl]-1H-pyridin-2-one	1601029: Inhibition of IP6K2 (unknown origin) in presence of ATP at Km concentration by Cheng-Prusoff equation analysis	ki	4.8800	uM
5,7-dihydroxy-2-(4-methoxyphenyl)chromen-4-one	1572024: Inhibition of human IP6K2 using insP6 as substrate preincubated for 15 mins followed by substrate and measured after 30 mins by TR-FRET assay	ic50	5.7000	uM
(E)-3-[3-(4-methylphenyl)-2,1-benzoxazol-5-yl]prop-2-enoic acid	1909469: Inhibition of N-terminal 6His-tagged/TEV cleavage site fused recombinant human IP6K2 expressed in Escherichia coli assessed as inorganic phosphate release using InsP6 as substrate in presence of ATP measured after 60 to 120 mins by malachite green based colorimetric - DIPP1 coupled enzyme assay	ic50	6.5100	uM
5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one	1572024: Inhibition of human IP6K2 using insP6 as substrate preincubated for 15 mins followed by substrate and measured after 30 mins by TR-FRET assay	ic50	7.1000	uM
2-(3,4-dihydroxyphenyl)-5-hydroxychromen-4-one	1572024: Inhibition of human IP6K2 using insP6 as substrate preincubated for 15 mins followed by substrate and measured after 30 mins by TR-FRET assay	ic50	8.0000	uM
(E)-3-(3-phenyl-2,1-benzoxazol-5-yl)prop-2-enoic acid	1909469: Inhibition of N-terminal 6His-tagged/TEV cleavage site fused recombinant human IP6K2 expressed in Escherichia coli assessed as inorganic phosphate release using InsP6 as substrate in presence of ATP measured after 60 to 120 mins by malachite green based colorimetric - DIPP1 coupled enzyme assay	ic50	8.6500	uM

CTD chemical–gene interactions

47 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases expression, decreases methylation	4
Arsenic	increases abundance, affects methylation, affects cotreatment, increases expression, decreases expression	3
Estradiol	affects expression, decreases expression	3
aristolochic acid I	increases expression	1
3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide	decreases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	affects expression	1
beta-lapachone	increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
sodium arsenite	decreases expression, increases abundance	1
cobaltous chloride	increases expression	1
potassium chromate(VI)	affects cotreatment, increases expression	1
2,3-bis(3’-hydroxybenzyl)butyrolactone	affects cotreatment, decreases expression	1
beta-methylcholine	affects expression	1
epigallocatechin gallate	increases expression, affects cotreatment	1
di-n-butylphosphoric acid	affects expression	1
ICG 001	decreases expression	1
abrine	increases expression	1
Grape Seed Proanthocyanidins	affects cotreatment, decreases expression	1
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	increases expression, increases response to substance	1
bisphenol S	increases methylation	1
PCI 5002	affects cotreatment, increases expression	1
Air Pollutants	decreases expression	1
Catechin	affects cotreatment, decreases expression	1
Coumestrol	decreases expression, affects cotreatment	1
Dichlorodiphenyl Dichloroethylene	decreases expression	1
Ethyl Methanesulfonate	increases expression	1
Formaldehyde	increases expression	1
Gallic Acid	increases expression	1
Iron	affects cotreatment, increases expression	1

ChEMBL screening assays

16 unique, capped per target: 16 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4370053	Binding	Inhibition of human IP6K2 using insP6 as substrate preincubated for 15 mins followed by substrate and measured after 30 mins by TR-FRET assay	Inhibition of Inositol Polyphosphate Kinases by Quercetin and Related Flavonoids: A Structure-Activity Analysis. — J Med Chem

Cellosaurus cell lines

3 cell lines: 3 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B1UL	Abcam HeLa IP6K2 KO	Cancer cell line	Female
CVCL_D8NA	Ubigene HCT 116 IP6K2 KO	Cancer cell line	Male
CVCL_E0F9	Ubigene HeLa IP6K2 KO	Cancer cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.